$CLPT News

Last published 2w ago

2w agoCLPTClearPoint Neuro, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
2w agoCLPTClearPoint Neuro Reports Third Quarter 2026 ResultsACCESS NewswireNeurosurgery Navigation & Therapy Grew 59% to $5.4 Million SOLANA BEACH, CA / ACCESS Newswire / October 28, 2026 / ClearPoint Neuro, Inc. , a global device, cell, and gene
4w agoCLPTClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026ACCESS NewswireSOLANA BEACH, CA / ACCESS Newswire / October 14, 2026 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and
3mo agoCLPTSecond Quarter 2026 Financial Results - CLEARPOINT NEURO INCEarnings Call TranscriptsComments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-thinking statements may include, without limitation, the company's plans, prospects, and str
3mo agoCLPTClearPoint Neuro Reports Second Quarter 2026 ResultsACCESS NewswirePositive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (the
3mo agoCLPTClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SasineprocelACCESS NewswireRMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire / July 31,
3mo agoCLPTClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026ACCESS NewswireSOLANA BEACH, CA / ACCESS Newswire / July 21, 2026 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and
4mo agoCLPT ICCM NTHI QUREBiotech's New Frontier: Companies Breaking Through Medicine's Toughest BarriersGlobeNewswireDENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene
5mo agoCLPTClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global FootprintACCESS NewswireAnnouncement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including both focused
6mo agoCLPTClearPoint Neuro Reports First Quarter 2026 ResultsACCESS NewswireRecord Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. , a global device, cell, and
6mo agoCLPTClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global FootprintACCESS NewswireSOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today
6mo agoCLPTClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026ACCESS NewswireSOLANA BEACH, CA / ACCESS Newswire / April 29, 2026 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine,
6mo agoCLPTClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global FootprintACCESS NewswireSOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today
6mo agoCLPTClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global FootprintACCESS NewswireCombined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's overall global
7mo agoCLPTClearPoint Neuro Reports Fourth Quarter and Full Year 2025 ResultsACCESS NewswireRecord Revenue and IRRAS Holdings Acquisition Highlight the Company's 'Fast. Forward.' StrategySOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. , a global device,
8mo agoCLPTClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026ACCESS NewswireSOLANA BEACH, CA / ACCESS Newswire / March 6, 2026 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine,
10mo agoCLPTClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 RevenueACCESS NewswireThe Company Achieved 20% Comparable Sales Growth in the Fourth Quarter of 2025 at $10.4 MillionSOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 12, 2026 / ClearPoint Neuro, Inc. , a
11mo agoCLPTClearPoint Neuro Completes Acquisition of IRRASACCESS NewswireAcquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 20, 2025
1y agoCLPTClearPoint Neuro Reports Third Quarter 2025 ResultsACCESS NewswireSite Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization SOLANA BEACH, CA / ACCESS Newswire / November 6, 2025
1y agoCLPTClearPoint Neuro Announces Agreement to Acquire IRRASACCESS NewswireAcquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment of Intracranial
1y agoCLPTClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025ACCESS NewswireSOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 5, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the
1y agoCLPTClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los AngelesACCESS NewswireSOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the
1y agoCLPTClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries WorldwideACCESS NewswireThe clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October
1y agoCLPTClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation SystemACCESS NewswireNew Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene Therapy SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 1, 2025 / ClearPoint Neuro, Inc. (the
1y agoCLPTClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical OfficerACCESS NewswireSOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 25, 2025 / ClearPoint Neuro, Inc.
1y agoCLPTClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI ScannersACCESS NewswireSOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 4, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the
1y agoCLPTClearPoint Neuro, Inc. (CLPT) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoCLPTClearPoint Neuro Reports Second Quarter 2025 ResultsACCESS NewswireRecord Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / August 12, 2025 / ClearPoint Neuro, Inc. ,
1y agoCLPTClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery PortfolioACCESS NewswireSOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain
1y agoCLPTClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025ACCESS NewswireSOLANA BEACH, CALIFORNIA / ACCESS Newswire / July 23, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the
1y agoCLPTClearPoint Neuro Reports First Quarter 2025 ResultsACCESS NewswireRecord Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. , a global
1y agoCLPTClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at ClosingACCESS NewswireSOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the
1y agoCLPTClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRIACCESS NewswireSOLANA BEACH, CA / ACCESS Newswire / April 28, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and
1y agoCLPTClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025ACCESS NewswireSOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and
1y agoCLPTClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 – Delivering the First End-to-End ClearPoint Navigation Solution to the Operating RoomACCESS NewswireThe platform will be showcased at the American Academy of Neurological Surgeons Annual Meeting in Boston on April 25-28, 2025. SOLANA BEACH, CALIFORNIA / ACCESS Newswire / April 24, 2025 / ClearPoint Neuro, Inc.
1y agoCLPTClearPoint Neuro Reports Fourth Quarter and Full Year 2024 ResultsACCESS NewswireAchieved Record Revenue for 2024 and Growth of 31%;Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (the
1y agoCLPTClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025ACCESS NewswireSOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain
1y agoCLPTClearPoint Neuro Announces EU MDR Certification for the SmartFlow CannulaACCESS NewswireSOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain
1y agoCLPTClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0ACCESS NewswireSOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the
1y agoCLPTFDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase DeficiencyFDA Press ReleasesThe U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the field of gene therapy contin ...
1y agoCLPTClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the BrainACCESS NewswireOnly Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (the
2y agoCLPTClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoCLPTClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024ACCESS NewswirePresident and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (the
2y agoCLPTClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024GlobeNewswireSOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine,
2y agoCLPTClearPoint Neuro Announces Early Repayment of $10 Million NoteGlobeNewswireSOLANA BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine,
2y agoCLPTClearPoint Neuro, Inc. (CLPT) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoCLPTClearPoint Neuro Reports Second Quarter 2024 ResultsGlobeNewswireSOLANA BEACH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today
2y agoCLPTClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024GlobeNewswireSOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine,
2y agoCLPTClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical TrialGlobeNewswireSOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine,
2y agoCLPTParkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement NeuronsPR NewswireAspen Neuroscience, Inc. announced today that it is utilizing the MRI-guided ClearPoint® Navigation System for all patients enrolled in the recently...